Colorectal Cancer Yields to Dual HER2 Blockade

Area of Science:

• Oncology
• Gastrointestinal Cancers
• Molecular Targeted Therapy

Background:

• Metastatic colorectal cancer (mCRC) with HER2-positive and KRAS-wild-type profiles presents a therapeutic challenge.
• Previous treatments with epidermal growth factor receptor (EGFR) inhibitors like cetuximab and panitumumab have shown limited efficacy in this patient subgroup.
• The role of HER2-targeted therapies in mCRC requires further investigation.

Purpose of the Study:

• To evaluate the efficacy of a combination anti-HER2 therapy in patients with KRAS-wild-type, HER2-positive metastatic colorectal cancer.
• To assess the response rate to dual HER2 blockade in patients refractory to standard EGFR inhibitors.

Main Methods:

• A Phase II clinical study was conducted.
• Participants received a combination of trastuzumab and lapatinib.
• Patient selection criteria included KRAS-wild-type and HER2-positive status, with prior resistance to cetuximab or panitumumab.

Main Results:

• The anti-HER2 combination therapy demonstrated clinical activity.
• An objective response rate of 30% was observed in the study population.
• No responses were seen with prior standard EGFR inhibitor treatment.

Conclusions:

• Trastuzumab and lapatinib combination therapy is an active treatment strategy for HER2-positive, KRAS-wild-type metastatic colorectal cancer.
• Dual HER2 blockade offers a viable therapeutic option for patients who have progressed on EGFR inhibitors.
• Further research into HER2-targeted therapies in mCRC is warranted.